CMC DEVELOPMENT PLAN UPDATED (CP/ADDS) (1/2)

GLOBAL DRUG DEVELOPMENT

Goals/ Definition

A detailed plan for completing the initial design and characterization of the combination product at EP1 stage gate.

CMC development plan updated.

CRITERIA	SAMPLE CONTENT REQUIREMENT		GUIDELINES FOR LEVEL OF DETAIL NEEDED AT EACH GATE
▪ List of activities that will be conducted, that lead to achieving Product Definition and Planning milestone at EP1 stage gate	Plans to complete the following bolded items by the next stage gate: • User capabilities and preferences assessment • Ethnographic studies completion • Hazard identification initiation • Concept assessment completion • Design and development plan initiation • Instructions for Use drafts • Human Factors Study Plan • Application risk assessment completion • Design History File initiation • Design Input Review completion • High-level Project Plan and definition of critical product attributes (if prototype available) • Preliminary device prototype generation • **Design Output Review completion** • **Formative human factors study completion** • **Design risk assessment completion** • **Process risk assessment initiated** • **Critical component dimensions and specifications definition** • **Design and Development Plan updates** • **Instructions for Use updates** • **Design History File updates**	• **Engineering testing of prototype and conduct simulated use or clinical testing** • Summative human factors study initiated • Design verification execution • Design Verification Review completion • Design validation execution • Design Validation Review completion • Design transfer completion • Design Transfer Review completion • Supply chain / logistics plan completion • Complaint handling process definition • Pharmacovigilance plan completion	▪ A detailed plan to achieve the FIH CMC milestones is expected ▪ Additionally, the plan should identify potential development risks to launch and risk mitigation strategies related to development timeline, costs, and resource allocation

CMC DEVELOPMENT PLAN UPDATED (CP/ADDS) (2/2)

GLOBAL DRUG DEVELOPMENT

CRITERIA	SAMPLE CONTENT REQUIREMENT	GUIDELINES FOR LEVEL OF DETAIL NEEDED AT EACH GATE
▪ Instructions for Use drafted	a) Evaluation of appropriate labeling / packaging requirements for the combination product when they are single-entity (e.g., pre-filled syringes, vaginal rings), or physically combined and packaged together (e.g., drug vial with syringe with or without vial adapter) or for separate "cross-labeled" products (e.g., vial adaptor, finger flange with back stop) b) Confirmation that Instructions for Use addresses any use errors or residual user risk related to product safety and efficacy, which cannot be adequately mitigated by product re-design	▪ Summary report containing key data / information or information to substantiate conclusions ▪ Illustrative data tables or figures may be reported in an appendix
▪ Application risk assessment completed	a) Identification of potential use problems not apparent from analytical measurements, e.g., the demands associated with use exceed user capabilities b) Initial design review to evaluate adequacy of the design to fulfill intended application c) Appropriate risk mitigation strategies and definition of what residual risk is acceptable	
▪ High-level Project Plan created and critical product attributes (CPAs) defined (if prototype available)	a) Essential processes and equipment required for product development b) Development of prototype tooling and test equipment c) Review of product development plan to understand drug-device interface and alignment between drug stability and device shelf-life attributes. Determine if there are potential interactions between drug and device that would impact the performance/efficacy of the functioning of the device as well as the safety and efficacy of the drug action d) Initiate CMO / suppliers selection process	• Summary report containing key data / information or information to substantiate conclusions ▪ Illustrative data tables or figures may be reported in an appendix
▪ Preliminary device prototype generated	a) Development of early-stage device prototype for Formative Human Factor Studies	
▪ Review TPP	a) Review TPP developed and determine if modifications are necessary	

* Items in **bold** font reflect suggested reporting guidelines for this stage gate